Shots:
- The US FDA has granted IND clearance to SNUG01 for ALS
- SNUG01 will be evaluated in a P-I/IIa dose-escalation & expansion trial to assess its safety, tolerability, & preliminary efficacy in ALS adults; SineuGene to partner with academics & institutions to lead clinical development of SNUG01
- SNUG01, a TRIM72-targeted gene therapy, counteracts ALS through ROS scavenging, mitochondrial homeostasis, stress granule regulation, neuroinflammation inhibition, & membrane repair as shown in preclinical models while in an IIT trial, SNUG01 demonstrated safety, tolerability, & early efficacy
Ref: Prnewswire | Image: SineuGene
Related News:- GSK Reports the EMA’s Acceptance of Nucala (Mepolizumab) as an Add-on Treatment for COPD
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
